Since the Global Fund has shifted the focus of its 2012-2016 Strategy and investments towards “highest-impact countries,” the EECA has experienced a 15 percent reduction in health funding for three diseases. This is a bigger funding loss than in any other region. The Global Fund’s emphasis on disease burden and income level has meant decreased […]
For years the Global Fund has invested in co-infections and co- morbidities (COIMs) that undermine the impact of efforts to fight the three diseases, but without any overall framework for doing so. When new, powerful oral direct acting antivirals (DAAs) for hepatitis C treatment came to market, it pushed the Global Fund to reflect on […]
Good News! After long and tough discussions, our amendment on Hep C treatment to the Decision Point was accepted by SIIC. The amendment was then presented to the Board, which decided on the HEP C treatment now! The amended decision points look like follows: Decision Point GF/B32/DP07 The Board acknowledges the Strategy, Investment and Impact […]
Download below an Open Letter to the Global Fund Board in advance of its Thirty-Second Meeting, signed by 24 civil society organisations from around the world, detailing our grave concerns about the impact of the allocation methodology applied to Middle Income Countries (MICs) and the ultimate consequences on key affected populations. Open Letter Civil Society […]
The Global Fund could set a powerful example, by supporting countries who provide a technically sound case for using Global Fund resources to invest in hepatitis C treatment for co-infected people. Failure to support hepatitis C treatment will allow the epidemic to continue spreading while abandoning some of the world’s most marginalized people to die […]